Table 4.
Changes in biochemical data of study participants at 12 weeks after RYGB and VLCD.
| Variables | RYGB (n = 16) | VLCD (n = 15) | Median Difference (95% CI) | p-Value |
|---|---|---|---|---|
| FPG, mg/dL | ||||
| All patients | −16.5 (−30.0, −6.0) | −10.0 (−29.0, −3.0) | −12.0 (−53.3, 29.3) | 0.557 |
| Patients with T2D | −22.0 (−46.0, 5.0) | −118.0 (−136.0, −11.0) | 96 (−58.2, 250.2) | 0.195 |
| Patients without T2D | −9.0 (−28.0, −6.0) | −5.5 (−11.0, −2.0) | −2 (−18.6, 14.6) | 0.802 |
| HbA1c, % | ||||
| All patients | −0.5 (−0.9, −0.3) | −0.4 (−1.0, −0.0) | −0.2 (−1.6, 1.2) | 0.766 |
| Patients with T2D | −0.6 (−3.4, 0.0) | −4.1 (−6.0, −1.0) | 3.6 (−0.8, 7.9) | 0.100 |
| Patients without T2D | −0.5 (−0.7, −0.3) | −0.2 (−0.4, 0.0) | −0.2 (−0.6, 0.1) | 0.160 |
| Total cholesterol, mg/dL | −16.5 (−35.0, 5.5) | −24.0 (−44.0, 2.0) | 5 (−24.1, 34.1) | 0.727 |
| Triglyceride, mg/dL | −38.0 (−69.5, −12.0) | −22.0 (−54.0, −3.0) | −28 (−64.5, 8.5) | 0.128 |
| HDL cholesterol, mg/dL | −3.0 (−10.0, 7.5) | −5.0 (−13.0, 1.0) | 3 (−7.1, 13.1) | 0.550 |
| LDL cholesterol, mg/dL | −25.0 (−34.0, −9.0) | −28.0 (−35.0, 8.0) | −1 (−29.5, 27.5) | 0.943 |
| Uric acid, mg/dL | −0.7 (−1.5, 0.3) | 0.2 (−1.4, 0.9) | −0.9 (−2.5, 0.7) | 0.255 |
| Serum creatinine, mg/dL | 0.0 (−0.1, 0.1) | 0.0 (−0.1, 0.0) | 0 (−0.1, 0.1) | 0.776 |
| eGFR, mL/min/1.73 m2 | −0.2 (−4.6, 2.6) | 0.0 (−2.6, 3.0) | −0.3 (−5.6, 5) | 0.908 |
| AST, U/L | 4.0 (−2.0, 14.0) | −5.0 (−21.0, 0.0) | 9 (−6.3, 24.3) | 0.237 |
| ALT, U/L | 2.0 (−12.0, 9.0) | −17.0 (−31.0, −2.0) | 19 (1.1, 36.9) | 0.039 |
Data are presented as median (interquartile range) or mean difference (95% confidence interval). RYGB, Roux-en-Y gastric bypass; VLCD, very low-calorie diet; T2D, type 2 diabetes; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine transaminase.